The Fetal Safety of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers

Myla E Moretti, Daniela Caprara, Irina Drehuta, Emily Yeung, Stefanie Cheung, Lisa Federico, Gideon Koren, Myla E Moretti, Daniela Caprara, Irina Drehuta, Emily Yeung, Stefanie Cheung, Lisa Federico, Gideon Koren

Abstract

Angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are known to cause fetal renal damage in pregnancy. Due to conflicting reports in the literature, their safety after first trimester exposure has been debated. Our aim was to determine whether the use of ACE inhibitors or ARBs in the first trimester of pregnancy is associated with an increased risk for major malformations or other adverse outcomes. All subjects were prospectively enrolled from among women contacting a teratogen information service. At initial contact, details of maternal medical history and exposures were collected and follow-up interviews were conducted to ascertain pregnancy outcomes. Two comparator groups, women with hypertension treated with other antihypertensives, and healthy controls were also recruited. Baseline maternal characteristics were not different among the three groups. There were no differences in rates of major malformations. Both the ACE-ARBs and disease-matched groups exhibited significantly lower birth weight and gestational ages than the healthy controls (P < 0.001 for both variables). There was a significantly higher rate of miscarriage noted in the ACE/ARB group (P < 0.001). These results suggest that ACE inhibitors/ARBs are not major human teratogens; however, they may be associated with an increased risk for miscarriage.

References

    1. Zamorski MA, Green LA. NHBPEP report on high blood pressure in pregnancy: a summary for family physicians. American Family Physician. 2001;64(2):263–274.
    1. Roccella EJ. Report of the national high blood pressure education program working group on high blood pressure in pregnancy. American Journal of Obstetrics and Gynecology. 2000;183(1):S1–S22.
    1. Sibai BM, Lindheimer M, Hauth J, et al. Risk factors for preeclampsia, abruptio placentae, and adverse neonatal outcomes among women with chronic hypertension. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. The New England Journal of Medicine. 1998;339(10):667–671.
    1. Sibai BM, Abdella TN, Anderson GD. Pregnancy outcome in 211 patients with mild chronic hypertension. Obstetrics and Gynecology. 1983;61(5):571–576.
    1. Rey E, Couturier A. The prognosis of pregnancy in women with chronic hypertension. American Journal of Obstetrics and Gynecology. 1994;171(2):410–416.
    1. McCowan LME, Buist RG, North RA, Gamble G. Perinatal morbidity in chronic hypertension. British Journal of Obstetrics and Gynaecology. 1996;103(2):123–129.
    1. Ferrer RL, Sibai BM, Mulrow CD, Chiquette E, Stevens KR, Cornell J. Management of mild chronic hypertension during pregnancy: a review. Obstetrics and Gynecology. 2000;96(5):849–860.
    1. Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation: a Reference Guide to Fetal and Neonatal Risk. 9th edition. Baltimore, MD, USA: Lippincott, Williams & Wilkins; 2011.
    1. Magee LA, Ornstein MP, Von Dadelszen P. Management of hypertension in pregnancy. British Medical Journal. 1999;318(7194):1332–1336.
    1. Barr M., Jr. Teratogen update: angiotensin-converting enzyme inhibitors. Teratology. 1994;50(6):399–409.
    1. Quan A. Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists. Early Human Development. 2006;82(1):23–28.
    1. Cox RM, Anderson JM, Cox P. Defective embryogenesis with angiotensin II receptor antagonists in pregnancy. British Journal of Obstetrics and Gynaecology. 2003;110(11):1038–1040.
    1. Simonetti GD, Baumann T, Pachlopnik JM, von Vigier RO, Bianchetti MG. Non-lethal fetal toxicity of the angiotensin receptor blocker candesartan. Pediatric Nephrology. 2006;21(9):1329–1330.
    1. Biswas PN, Wilton LV, Shakir SW. The safety of valsartan: results of a postmarketing surveillance study on 12 881 patients in England. Journal of Human Hypertension. 2002;16(11):795–803.
    1. Bos-Thompson MA, Hillaire-Buys D, Muller F, et al. Fetal toxic effects of angiotensin II receptor antagonists: case report and follow-up after birth. Annals of Pharmacotherapy. 2005;39(1):157–161.
    1. Berkane N, Carlier P, Verstraete L, Mathieu E, Heim N, Uzan S. Fetal toxicity of valsartan and possible reversible adverse side effects. Birth Defects Research Part A. 2004;70(8):547–549.
    1. Briggs GG, Nageotte MP. Fatal fetal outcome with the combined use of valsartan and atenolol. Annals of Pharmacotherapy. 2001;35(7-8):859–861.
    1. Chung NA, Lip GY, Beevers M, Beevers DG. Angiotensin-II-receptor inhibitors in pregnancy. The Lancet. 2001;357(9268):1620–1621.
    1. Martinovic J, Benachi A, Laurent N, Daïkha-Dahmane F, Gubler MC. Fetal toxic effects and angiotensin-II-receptor antagonists. The Lancet. 2001;358(9277):241–242.
    1. From the Centers for Disease Control and Prevention. Postmarketing surveillance for angiotensin-converting enzyme inhibitor use during the first trimester of pregnancy—United States, Canada, and Israel, 1987–1995. Journal of the American Medical Association. 1997;277(15):1193–1194.
    1. Kreft-Jais C, Plouin PF, Tchobroutsky C, Boutroy MJ. Angiotensin-converting enzyme inhibitors during pregnancy: a survey of 22 patients given captopril and nine given enalapril. British Journal of Obstetrics and Gynaecology. 1988;95(4):420–422.
    1. Lip GYH, Churchill D, Beevers M, Auckett A, Beevers DG. Angiotensin-converting-enzyme inhibitors in early pregnancy. The Lancet. 1997;350(9089):1446–1447.
    1. Steffensen FH, Nielsen GL, Sorensen HT, Olesen C, Olsen J. Pregnancy outcome with ACE-inhibitor use in early pregnancy. The Lancet. 1998;351(9102):p. 596.
    1. Piper JM, Ray WA, Rosa FW. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors. Obstetrics and Gynecology. 1992;80(3 I):429–432.
    1. Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. The New England Journal of Medicine. 2006;354(23):2443–2451.
    1. Martin U, Foreman MA, Travis JC, Casson D, Coleman JJ. Use of ACE inhibitors and ARBs in hypertensive women of childbearing age. Journal of Clinical Pharmacy and Therapeutics. 2008;33(5):507–511.
    1. Andrade SE, Raebel MA, Brown J, et al. Outpatient use of cardiovascular drugs during pregnancy. Pharmacoepidemiology and Drug Safety. 2008;17(3):240–247.
    1. The Best Intentions: Unintended Pregnancy and the Well-Being of Children and Families. Washington, DC, USA: National Academy Press; 1995.
    1. Henshaw SK. Unintended pregnancy in the United States. Family Planning Perspectives. 1998;30(1):24–46.
    1. Ferris TF, Weir EK. Effect of captopril on uterine blood flow and prostaglandin E synthesis in the pregnant rabbit. Journal of Clinical Investigation. 1983;71(4):809–815.
    1. Scialli AR, Lione A. ACE inhibitors and major congenital malformations. The New England Journal of Medicine. 2006;355(12):p. 1280.
    1. Gilbert WM, Young AL, Danielsen B. Pregnancy outcomes in women with chronic hypertension: a population-based study. Journal of Reproductive Medicine for the Obstetrician and Gynecologist. 2007;52(11):1046–1051.
    1. Malm H, Artama M, Gissler M, et al. First trimester use of ACE-inhibitors and risk of major malformations. Reproductive Toxicology. 2008;26(1):p. 67.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다